Cabergoline is a prescription medication primarily used to treat hyperprolactinemia, a condition where the body produces too much of the hormone prolactin. It’s also used in some countries to treat Parkinson’s disease. The drug works by mimicking dopamine in the brain, which directly lowers prolactin levels and can restore normal hormonal function within weeks.
How Cabergoline Works
Prolactin is a hormone best known for triggering milk production after childbirth. But when prolactin levels climb too high outside of pregnancy or breastfeeding, it can cause a range of problems in both women and men. Cabergoline brings those levels back down by targeting a specific type of receptor in the pituitary gland called the D2 dopamine receptor.
Under normal circumstances, dopamine produced by the brain acts as a brake on prolactin release. In people with hyperprolactinemia, that brake isn’t working well enough. Cabergoline steps in as a powerful stand-in for dopamine, binding to D2 receptors with high specificity and signaling the pituitary to cut back on prolactin production. The effect is strong and long-lasting: cabergoline has an elimination half-life of 63 to 68 hours in healthy people, and even longer (79 to 115 hours) in people with hyperprolactinemia. That unusually long duration is why it only needs to be taken twice a week rather than daily.
Hyperprolactinemia: The Primary Use
High prolactin can stem from several causes. The most common is a prolactinoma, a small noncancerous tumor on the pituitary gland that overproduces the hormone. Certain medications, particularly some antipsychotics, can also raise prolactin levels significantly. Whatever the cause, the symptoms tend to follow a pattern.
In women, excess prolactin often disrupts menstrual cycles, sometimes stopping periods entirely. It can cause unwanted breast milk production (even without pregnancy), reduced sex drive, vaginal dryness, and difficulty getting pregnant. In men, it typically shows up as low libido, erectile dysfunction, and in some cases breast tissue growth. Over time, both men and women with untreated hyperprolactinemia can develop bone loss because the hormonal imbalance interferes with estrogen and testosterone.
Cabergoline is considered the first-line treatment for most cases of hyperprolactinemia. It normalizes prolactin in the majority of patients, and in many people with prolactinomas, it also shrinks the tumor itself. Once prolactin levels return to normal, symptoms like irregular periods, sexual dysfunction, and infertility often resolve.
Typical Dosing Schedule
The standard starting dose is 0.25 mg taken by mouth twice per week. If prolactin levels haven’t dropped to normal after about four weeks, the dose can be increased by 0.25 mg twice weekly. This gradual titration continues until blood tests show prolactin is in the normal range. The maximum recommended dose is 1 mg twice per week.
Because the drug stays active in your body for days, the twice-weekly schedule is easy to maintain compared to medications that require daily dosing. Most people take their doses on set days, like Tuesday and Saturday, to keep the interval consistent.
Fertility and Pregnancy
One of the most common reasons people are prescribed cabergoline is to restore fertility. High prolactin suppresses the hormonal signals that trigger ovulation, so women with hyperprolactinemia often struggle to conceive. By lowering prolactin, cabergoline can restart normal ovulatory cycles, and many women become pregnant during treatment.
If you’re trying to conceive, your prescriber will typically plan for you to stop cabergoline once pregnancy is confirmed. The goal is to use the medication long enough to normalize prolactin and allow conception, then discontinue it to minimize any exposure during pregnancy. Regular pregnancy testing is usually part of the monitoring plan for women of reproductive age taking this drug.
Use in Parkinson’s Disease
Because cabergoline activates dopamine receptors, it has also been studied and used for Parkinson’s disease, a condition caused by the loss of dopamine-producing brain cells. In a randomized trial of people newly diagnosed with Parkinson’s, cabergoline used alone improved motor symptoms in about 79% of patients after one year, compared to 86% on levodopa (the standard Parkinson’s medication). The difference was not statistically significant, meaning the two drugs performed comparably for many patients.
More than 60% of newly diagnosed Parkinson’s patients in the study were managed on cabergoline alone for up to a year, though 38% eventually needed supplemental levodopa by the 12-month mark. Cabergoline is not typically a first-choice Parkinson’s treatment today, partly because of cardiac safety concerns at the higher doses Parkinson’s requires (up to 4 mg daily, far more than the doses used for prolactin disorders). But it remains an option in certain clinical situations.
Common Side Effects
Most side effects of cabergoline relate to its dopamine activity. Nausea is the most frequently reported, especially when starting the medication or increasing the dose. Taking it with food or at bedtime can help. Dizziness, headache, and fatigue are also common in the early weeks of treatment.
Some people experience lightheadedness when standing up quickly, because cabergoline can lower blood pressure. Constipation and abdominal discomfort occur as well, though they tend to be mild. In the Parkinson’s trial, 76% of patients on cabergoline reported at least one adverse event compared to 66% on levodopa, suggesting side effects are fairly common but generally manageable enough that most people stay on the medication.
Heart Valve Monitoring
The most serious safety concern with long-term cabergoline use involves the heart valves. A meta-analysis published in The Journal of Clinical Endocrinology & Metabolism found that people treated with cabergoline for a year or more had higher rates of tricuspid valve regurgitation (a type of leaky heart valve) compared to untreated controls. Among those treated for at least a year, 20% had mild tricuspid regurgitation versus 11% of controls. The risk of moderate or severe leakage in the tricuspid valve was about 3.7 times higher in treated patients.
Importantly, none of the patients in the analysis developed valve problems severe enough to cause symptoms. And valves other than the tricuspid were largely unaffected: only 4 cases of moderate or severe aortic regurgitation were found across 766 treated patients (about 0.5%). Still, the risk is real enough that periodic echocardiograms (heart ultrasounds) are typically recommended for people on cabergoline long-term, especially at higher doses. The risk appears dose-related, so the relatively low doses used for hyperprolactinemia carry less concern than the higher doses once used for Parkinson’s disease.
How Long Treatment Lasts
For people with prolactinomas, treatment often continues for two years or more. After prolactin has been normal for an extended period, some prescribers will try a supervised withdrawal to see if levels stay down on their own. A significant portion of patients with smaller prolactinomas can eventually stop cabergoline without their prolactin rebounding, though regular blood work is needed to monitor for recurrence.
For medication-induced hyperprolactinemia or other non-tumor causes, treatment length depends on whether the underlying trigger can be addressed. If the offending medication can’t be changed, cabergoline may be needed indefinitely to keep prolactin in check.